We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Potent New Anticancer Agents Target Tumors in New Ways

By Biotechdaily staff writers
Posted on 05 Mar 2007
The search for new anticancer drugs has led scientists to synthesize a compound that works in a different way than existing agents and is so powerful that tiny levels of 10 parts per trillion block the growth of tumor cells in laboratory experiments. More...


Dr. Kazunori Koide and colleagues from the department of chemistry, University of Pittsburgh (PA, USA; www.pitt.edu) described the compound as one of the most potent of all anticancer agents in a study to be published in the March 7, 2007, issue of the Journal of the American Chemical Society.

The parent compound, FR901464, suppressed the growth of cancer cells implanted into laboratory mice. Because of structural similarity between FR901464 and their analogue, called meayamycin, the investigators are cautiously optimistic that meayamycin also will be effective against tumors in mice. The amount that the researchers utilized against cancer cells is equivalent to 10 seconds in 32,000 years or one packet of sugar (5 g) in a coffee cup the size of 400 Olympic-size pools.

In the article, researchers reported that existing chemotherapy medications work by targeting only a small number of exposed spots in a tumor, such as the DNA or hormone receptors. That limited range of targets has led scientists to seek new generations of drugs that work in different ways.


Related Links:
University of Pittsburgh

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Clinical Informatics Platform
CLARION™
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.